Biopharmaceutical contract manufacturing sales will expand through 2035, with mammalian-based systems at 72.3% of the platform category and monoclonal antibodies at 44.0% of product type demand in 2025. The market was valued at USD 11.23 billion in 2025 and is forecast to record an 8.8% CAGR between 2025 and 2035.